Guidance for human genome data collection, access, use and sharing

1:1

The ethical, legal, and equitable sharing of human genomic data is critical to advancing global health research and ensuring fair access to the benefits of genomics. The WHO’s new document outlines a comprehensive set of globally applicable principles designed to guide stakeholders in the responsible collection, use, and sharing of human genome data.

This document serves as a key resource to navigate complex issues surrounding data governance, with the aim of fostering transparency, promoting equity, and safeguarding individual and collective rights.

These principles are intended to support the implementation of best practices across diverse settings, thereby enhancing the global capacity for genomic research and its translation into health benefits for all.

Acces this publication (pdf)
Guidance for human genome data collection, access, use and sharing

Year of publication

2024

ISBN

9789240102149

Source

World Health Organization

Author

Research for Health (RFH), Technical Advisory Group on Genomics (TAG-G)

You might also be interested in

RealiseD webinars

RealiseD Webinar Series: Helping re‑shape rare disease clinical trials

13 January – 10 February 2026 | Online webinar series to advance best practices in clinical trial design for rare and ultra rare diseases.
P065130-367547

AFM‑Telethon launches its 2026 call to fund scientific and medical research in neuromuscular disorders

A funding opportunity for neuromuscular and rare genetic disease research is now open
Non-human primate hand via pickpik.com (CC0)

EMA public consultation on non‑human primate use in safety testing

EMA seeks stakeholder input on new reflection paper to reduce and replace non‑human primate use in medicines safety testing through 3Rs approaches.
abstract publication image on science health

Tailored antisense oligonucleotides for ultrarare CNS diseases: An experience-based best practice framework for individual patient evaluation

Outside traditional drug development pathways, clinicians and scientists face the challenge of systematically evaluating whether individual patients with severe ultrarare diseases might be eligible for and potentially benefit from individualized mutation-specific RNA therapies.

ERDERA's

search form